hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
Company Information
About this company
Key people
Yamin Mohammed Khan
Chief Executive Officer, Executive Director
Stephen Pinkerton
Chief Financial Officer, Executive Director
Shaun Edward Chilton
Non-Executive Chairman of the Board
Brendan Mary Buckley
Non-Executive Director
Richard John Cotton
Independent Non-Executive Director
Elaine Sullivan
Senior Independent Non-Executive Director
Click to see more
Key facts
- Shares in issue687.01m
- EPICHVO
- ISINGB00B9275X97
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap£42.61m
- Employees301
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.